Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00428285 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv13
  2. Study Status, Referencesv12
  3. Study completion date changed from estimate of Dec 2015 to Jul 2016 Trial status: Active, Not Recruiting to Completedv11 Show all 2 changesShow less
    • Trial status: Active, Not Recruiting to Completed
  4. Completion date: Jun 2015 to Dec 2015v10
  5. Primary completion date changed from estimate of Jun 2009 to Feb 2010 Completion date: Jun 2009 to Jun 2015v9 Show all 2 changesShow less
    • Completion date: Jun 2009 to Jun 2015
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Jun 2009 · Secondary endpoints: 1 to 2 · Site details revised at 2 of 2 sitesv7 Show all 4 changesShow less
    • Primary completion date: Jun 2009
    • Secondary endpoints: 1 to 2
    • Site details revised at 2 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Primary endpoint revised Eligibility criteria expanded, about 7 words · Secondary endpoint revised · Study title shortened, about 7 words · 2 morev6 Show all 6 changesShow less
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoint revised
    • Study title shortened, about 7 words
    • Study arms: 0 to 1
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study description revisedv5 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  5. Secondary endpoint revised Primary endpoint revised · Eligibility criteria expanded, about 5 words · Study description shortened, about 1 word · 1 morev4 Show all 5 changesShow less
    • Primary endpoint revised
    • Eligibility criteria expanded, about 5 words
    • Study description shortened, about 1 word
    • Study title expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  6. Trial status: Not Yet Recruiting to Recruiting Site details revised at 2 of 2 sitesv3 Show all 2 changesShow less
    • Site details revised at 2 of 2 sites
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess if argon plasma coagulation (APC) is a safe and well tolerated treatment method for anal intraepithelial neoplasia (AIN) grade 2/3 in HIV-positive men having sex with men (MSM).
Trial Details
NCT Number NCT00428285
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, CIHR Canadian HIV Trials Network
Conditions Anus Neoplasms, HIV Infections
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov